Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nasdaq  >  Incyte Corporation    INCY   US45337C1027

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
Latest news on INCYTE CORPORATION
07/17 INCYTE : Joins Forces with Vanderbilt University Medical Center
07/15 INCYTE : and Vanderbilt University Medical Center Establish Multi-Year Oncology ..
07/14 INCYTE : to Report Second Quarter Financial Results on August 4
07/10 INCYTE : Partners with Vanderbilt University Medical Center
07/07 INCYTE : and Vanderbilt University Medical Center Establish Multi-Year Oncology ..
07/07 INCYTE : and Vanderbilt University Medical Center Establish Multi-Year Oncology ..
06/25 INCYTE : Assigned Patent
06/19 INCYTE : Change in Directors or Principal Officers (form 8-K)
06/19 INCYTE : Announces Organizational and Management Changes to Drive Future Global ..
06/18 INCYTE : Navitor Pharmaceuticals Appoints Dr. Paul Friedman to Its Board of Dire..
06/17 ELI LILLY : Lilly and Incyte unveil detailed data on two pivotal studies of bari..
06/11 INCYTE : Advaxis Announces FDA Clearance of Investigational New Drug Application..
06/03 INCYTE : Clinical Portfolio to be Featured in 23 Abstract Presentations at the 2..
06/03 ELI LILLY : Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III D..
06/01 INCYTE : Advaxis Announces FDA Clearance of Investigational New Drug Application..
05/28 INCYTE : Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data
05/27 INCYTE : Clinical Portfolio to be Featured in 23 Abstract Presentations at the 2..
05/22 INCYTE : Submission of Matters to a Vote of Security Holders (form 8-K)
05/21 INCYTE : Assigned Patent
05/08 INCYTE : Biotech Equities Ahead of Market -- Biocept, Athersys, Biogen, Dyax Cor..
05/04 INCYTE : Change in Directors or Principal Officers (form 8-K)
04/30 INCYTE : Management's Discussion and Analysis of Financial Condition and Results..
04/30 INCYTE : reports 1Q loss
04/30 INCYTE : Results of Operations and Financial Condition, Financial Statements and..
04/30 INCYTE : Reports 2015 First-Quarter Financial Results and Updates Shareholders o..
04/29 AGENUS : Reports First Quarter 2015 Financial Results
04/29 INCYTE : Emerging Development Pipeline Described in Eleven Abstracts at 2015 AAC..
04/23 INCYTE : to Present at Upcoming Investor Conferences
04/23 INCYTE : Agenus Reports First Quarter 2015 Financial Results
04/17 INCYTE : Other Events, Financial Statements and Exhibits (form 8-K)
04/17 INCYTE : Emerging Development Pipeline Described in Eleven Abstracts at 2015 AAC..
04/17 INCYTE : Emerging Development Pipeline Described in Eleven Abstracts at 2015 AAC..
04/15 INCYTE : Assigned Patent
04/14 INCYTE : to Report First Quarter Financial Results on April 30
04/14 INCYTE : to Establish European Headquarters in Geneva, Switzerland
04/14 INCYTE : to Establish European Headquarters in Geneva, Switzerland
04/13 INCYTE : Change in Directors or Principal Officers (form 8-K)
03/26 INCYTE : Jakavi (ruxolitinib) Gets European Commission Approval as First Targete..
03/24 INCYTE : Morning Analysis on Biotech Equities -- Hemispherx Biopharma, Celldex T..
03/20 INCYTE : Jakavi (ruxolitinib) Receives European Commission Approval as First Tar..
03/17 INCYTE : Jakavi® (ruxolitinib) Receives European Commission Approval as First Ta..
03/11 INCYTE : Appoints Steven H. Stein, MD as Chief Medical Officer
03/08 INCYTE : Sponsors Observational Study on Polycythemia Vera
03/04 ELI LILLY : Baricitinib Superior to Placebo in Reducing Rheumatoid Arthritis Dis..
03/04 INCYTE : Sponsors First Observational Study Designed to Understand the Impact of..
03/03 INCYTE : Sponsors Observational Study on Polycythemia Vera
03/03 Agenus Posts Fourth Quarter and Full Year 2014 Financial Results
03/02 INCYTE : Appoints Steven H. Stein, MD as Chief Medical Officer
03/02 INCYTE : Sponsors First Observational Study Designed to Understand the Impact of..
02/26 INCYTE : Sponsors First Observational Study Designed to Understand the Impact of..
02/23DJELI LILLY : Lilly, Incyte Rheumatoid Arthritis Drug Meets Endpoint
02/20 INCYTE : Other Events (form 8-K)
02/17 INCYTE : to Present at Upcoming Investor Conferences
02/12 INCYTE : reports 4Q loss
02/12 INCYTE : Results of Operations and Financial Condition, Financial Statements and..
02/12 INCYTE : Reports 2014 Fourth-Quarter and Year-End Financial Results; Provides 20..
02/11 INCYTE : Earns $25 Million Milestone as Jakavi® (ruxolitinib) Recommended for Ap..
02/11 INCYTE : Advaxis Forms Clinical Trial Collaboration With Incyte to Evaluate Inve..
02/10 INCYTE : Today's Review on Biotech Equities - Vertex Pharma, Alexion Pharma, Arr..
02/07 INCYTE : New England Journal of Medicine Releases Results from Incyte's Phase II..
02/04 INCYTE : Earns $25 Million Milestone as Jakavi® ruxolitinib Recommended for Appr..
02/02 INCYTE : New England Journal of Medicine Issues Results from Incyte's Phase III ..
01/31 INCYTE : to Collect $25 Million Milestone Payment from Novartis
01/29 INCYTE : to Collect $25 Million Milestone Payment from Novartis
01/28 INCYTE : Announces Publication of Phase III RESPONSE Trial in Patients with Poly..
01/27 INCYTE : to Report Fourth Quarter/Year-End 2014 Financial Results on February 12
01/26 INCYTE : Change in Directors or Principal Officers (form 8-K)
01/23 UNILIFE : Appoints David Hastings as Chief Financial Officer
01/23 INCYTE : and Agenus Announce Global Alliance to Develop Novel Immuno-Oncology An..
01/23 INCYTE : Earns $25 Million Milestone as Jakavi® (ruxolitinib) Recommended for Ap..
01/21 INCYTE : Diagnostics Selects Don Larsen as New CEO
01/20 INCYTE : Diagnostics Selects Don Larsen as New CEO
01/18 INCYTE : Board Adds 2 New Directors
01/14 INCYTE : Board Names 2 New Directors
01/13 UNILIFE : Appoints David Hastings as Chief Financial Officer
1  2  3  4  5Next
Advertisement
Chart
Duration : Period :
Incyte Corporation Technical Analysis Chart | INCY | US45337C1027 | 4-Traders
Income Statement Evolution
More Financials